What will the average number of measles cases be during Trump's term?
I assess a better-than-even (65%) probability that the 2025–2028 average annual measles case count in the U.S. will be at or above ~2,288 cases/year, driven by the 2025 record, a large 2026 mid‑year total, persistent transmission chains, and weakened/fragmented public‑health countermeasures.
Analysis
**Stage 1 — Blind analysis (ignore market prices):**
The factual starting points are: 2025 produced a record high ~2,288 confirmed measles cases; 2026 is already high with 1,814 confirmed by mid‑July and multiple geographically dispersed outbreaks; experts report outbreaks that are more persistent and, in some places, continuous for more than a year. These indicate both larger outbreak seedings (importations) and degraded ability to rapidly extinguish chains of transmission in some communities.
Key mechanisms that make a high 4‑year average plausible:
- *Momentum and persistence.* High case counts in successive years (2025 then a large 2026 midway count) make it more likely that 2027–2028 will not uniformly revert to pre‑2019 low levels. Measles is extremely transmissible; once sustained community spread occurs in undervaccinated pockets, repeated seeding and chain extension are more probable.
- *Heterogeneous vaccine coverage and pockets of susceptibility.* Outbreaks continue to be driven by localized undervaccination (by geography, community, or institutional settings such as detention centers). National averages can remain elevated if multiple pockets independently sustain outbreaks each year.
- *International travel & importations.* The continuing role of travel importations keeps reintroducing measles into susceptible networks, sustaining case counts even if local public‑health responses are active.
- *Public‑health capacity & policy risks.* Reported criticisms of the federal administration’s health policy and potential declines in insurance coverage or local health resources raise the plausibility of slower/more fragmented outbreak responses, increasing the chance of sustained higher case loads.
Balancing factors that argue against the 2,288+ average:
- *Concentration of cases.* Historically, even large U.S. measles years have been concentrated in limited geographies or communities; national totals can fall rapidly if public‑health teams mount targeted responses, vaccine catch‑up campaigns, school exclusion/mandates, and local political pressure.
- *Reversion risk & stochasticity.* Measles outbreaks can be bursty: a very bad year can be followed by a milder year if immunity gaps are closed or if the chains of transmission burn out. This means a single record year (2025) does not guarantee multi‑year elevated averages.
- *Behavioral and policy countermeasures.* Heightened public attention after a record year can produce stronger local vaccination drives, catch‑up campaigns, or reinstated school mandates that materially reduce cases in subsequent years.
Synthesis and blind probability estimate: taking the large observed 2025 baseline, the already‑high 2026 picture through mid‑year, the persistent transmission reports, and structural risks to public‑health capacity — but also accounting for possible targeted mitigation and historical concentration of outbreaks — my independent estimate that the 2025–2028 average will equal or exceed ~2,288 cases/year is **65%**. That reflects my reading that sustained elevated transmission is more likely than rapid reversion to lower historical means across all four years, but not overwhelmingly certain because of plausible effective countermeasures and year‑to‑year volatility.
**Stage 2 — Market calibration (compare to current market price Yes = 0.34):**
The current market price (Yes 34%) prices in a substantially lower probability than my independent view (65%). Possible reasons the market is lower:
- *Reversion bias / mean‑reversion expectation.* Many traders may anchor on historical pre‑2025 averages (much lower than 2,288) and assume 2025 was an outlier that will not persist.
- *Under‑weighting of 2026 data.* Traders may not have fully incorporated the 1,814 mid‑year 2026 total or the qualitative reports of persistent chains into probabilities, treating 2026 as salvageable by end‑year response.
- *Liquidity and retail crowding.* The market may be driven by retail participants who prefer binary, short‑term narratives (e.g., 'public health will respond') and who do not internalize systemic changes (weakened vaccination infrastructure, policy shifts) that support sustained elevation.
- *Ambiguity about the question/threshold.* If some participants are uncertain about the precise threshold or averaging period, they may discount the 'Yes' side.
Why the market might be right despite my higher estimate:
- *Effective targeted responses are historically powerful.* Localized catch‑up campaigns and school exclusion policies can, and have, rapidly reduce transmission in following seasons; traders may be rationally pricing that probability.
- *Optimism about replenished vaccination momentum.* A record year can spur higher vaccination uptake among the hesitant, yielding faster reductions than I assume.
Given these considerations, the market appears to underprice the plausible sustained‑high scenario. If you believe persistence of multiple, geographically independent outbreaks and continuing importations, the market offers value on the Yes side. Conversely, if you place more weight on rapid mitigation and mean‑reversion, the current market price may be reasonable.
In short: my independent probability is 65% (Yes). The market at ~34% signals either an underestimation of persistence and systemic risk or a heavier weighting of potential successful countermeasures. I lean toward the former, so I view Yes at current market prices as undervalued.
Arguments
For
- Large recent baseline years (2025 record; strong 2026 mid‑year) make a high 4‑year average numerically easier to reach and maintain.
- Reports of outbreaks that are harder to extinguish and sustained transmission for >1 year increase the chance of endemic‑like repeat outbreaks across multiple years.
- Multiple, geographically distributed outbreaks and continued importations reduce the likelihood that a single localized intervention will normalize national totals.
- Potential weakening of public‑health capacity and shifts in health policy increase risk of slower identification, response, and vaccination efforts.
Against
- Measles outbreaks in the U.S. have historically been highly concentrated; national totals can fall quickly if public‑health authorities run targeted campaigns in affected communities.
- A single record year does not guarantee multi‑year high averages — stochastic dynamics can cause rapid reversion if transmission chains burn out.
- Increased public awareness after a record year often triggers local mitigation and higher vaccination uptake, which could substantially lower cases in subsequent years.
- If vaccination policy or enforcement is tightened (school mandates, workplace requirements), pockets of susceptibility could shrink faster than currently expected.
Key drivers
- Observed 2025 record (2,288 cases) and 2026 mid‑year total (1,814) that establish a high baseline and momentum
- Persistence of outbreaks and evidence of >1 year sustained transmission in some communities
- Vaccination coverage heterogeneity and undervaccinated pockets that allow recurring outbreaks
- Public‑health capacity, policy choices, and socioeconomic factors (insurance loss, closures) that can weaken outbreak response
Risk factors
- Rapid, targeted public‑health responses (catch‑up vaccination campaigns, school exclusion, outbreak containment) that could reduce future annual totals
- Behavioral change after a record year leading to increased vaccine uptake
- Stochastic burnout of transmission chains in critical clusters leading to sharp year‑to‑year declines
- Data/reporting variability or changes in case classification that alter comparable annual totals
Scenarios
Best case
Measles becomes more broadly endemic and multiple sustained transmission chains continue through 2027–2028, with national annual counts staying at or above the 2025 benchmark each year. The average 2025–2028 therefore meets or exceeds ~2,288, driven by repeated large outbreaks, weak containment in key pockets, continuous importations, and limited scale‑up of vaccine coverage.
Most likely
2025 is a high anchor year, 2026 ends comparably high (within ±20% of 2025), and 2027–2028 see modest declines as targeted responses have mixed success. The multi‑year average sits near the threshold — somewhat above or below 2,288 depending on the scale of responses — with a moderate tilt toward staying above the threshold (consistent with my 65% estimate).
Worst case
Aggressive, well‑coordinated public‑health interventions, renewed vaccine mandates, and community mobilization rapidly close immunity gaps. 2026 ends lower than 2025, and 2027–2028 see substantially fewer cases, pulling the four‑year average below 2,288. Reporting or classification changes could also artificially depress counts.
More from this day
- pop culturePolymarketEnded
"Evil Dead Burn" Opening Weekend Box Office
AI22%MKT96%Edge-74HypedEvil Dead Burn looks more likely to finish above $20 million than below it, even with Moana in the same frame. The current market is pricing a sub-$20 million opening as almost certain, but the available tracking and franchise comps point to a meaningfully higher opening.
- PoliticsKalshi2y
Which agencies will Trump eliminate?
AI99%MKT34%Edge+65Hidden GemUSAID has already been functionally eliminated as an independent agency (shuttered July 1, 2025 and folded into State); I assess a ~99% chance it will be counted as eliminated during Trump’s term.
- PoliticsKalshi18y
Which G7 leader will leave next?
AI35%MKT98%Edge-63HypedI assess ~35% chance the UK Prime Minister (Keir Starmer) will be the first G7 leader to leave office; the market at ~98% for that outcome looks severely overstated given scheduled election timing and relative stability of other leaders.